IL138154A0 - Pharmaceutical compositions containing sodium [[3- (2-amino-1,2-dioxoethyl) -2-ethyl-1-) phenylmethyl) -1h-indol-4-yl]oxy] acetate - Google Patents

Pharmaceutical compositions containing sodium [[3- (2-amino-1,2-dioxoethyl) -2-ethyl-1-) phenylmethyl) -1h-indol-4-yl]oxy] acetate

Info

Publication number
IL138154A0
IL138154A0 IL13815499A IL13815499A IL138154A0 IL 138154 A0 IL138154 A0 IL 138154A0 IL 13815499 A IL13815499 A IL 13815499A IL 13815499 A IL13815499 A IL 13815499A IL 138154 A0 IL138154 A0 IL 138154A0
Authority
IL
Israel
Prior art keywords
dioxoethyl
phenylmethyl
indol
oxy
acetate
Prior art date
Application number
IL13815499A
Other languages
English (en)
Original Assignee
Shionogi & Co
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co, Lilly Co Eli filed Critical Shionogi & Co
Publication of IL138154A0 publication Critical patent/IL138154A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13815499A 1998-03-03 1999-03-02 Pharmaceutical compositions containing sodium [[3- (2-amino-1,2-dioxoethyl) -2-ethyl-1-) phenylmethyl) -1h-indol-4-yl]oxy] acetate IL138154A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03
PCT/US1999/004516 WO1999044604A1 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Publications (1)

Publication Number Publication Date
IL138154A0 true IL138154A0 (en) 2001-10-31

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13815499A IL138154A0 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing sodium [[3- (2-amino-1,2-dioxoethyl) -2-ethyl-1-) phenylmethyl) -1h-indol-4-yl]oxy] acetate

Country Status (21)

Country Link
US (1) US6166062A (zh)
EP (1) EP1058547B1 (zh)
JP (3) JP2002505282A (zh)
KR (1) KR20010034552A (zh)
CN (1) CN1299277A (zh)
AT (1) ATE310513T1 (zh)
AU (1) AU757002B2 (zh)
BR (1) BR9908479A (zh)
CA (1) CA2322796A1 (zh)
DE (1) DE69928500T2 (zh)
EA (1) EA003864B1 (zh)
ES (1) ES2253877T3 (zh)
HU (1) HUP0102812A3 (zh)
ID (1) ID27487A (zh)
IL (1) IL138154A0 (zh)
NO (1) NO20004306L (zh)
NZ (1) NZ506578A (zh)
PL (1) PL342822A1 (zh)
TR (1) TR200002543T2 (zh)
TW (1) TW570795B (zh)
WO (1) WO1999044604A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
EP1265607A2 (en) * 2000-03-09 2002-12-18 Eli Lilly And Company METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
BRPI0509592A (pt) * 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
PE20120476A1 (es) 2006-06-09 2012-04-20 Sanol Arznei Schwarz Gmbh Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PL2111124T3 (pl) * 2007-02-12 2012-05-31 Lassaad Boujbel Jałowy roztwór sukralozy bez środków konserwujących i sposób jego wytwarzania
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
DE69421936T2 (de) * 1993-10-27 2000-06-29 Upjohn Co Stabilisiertes prostaglandin e1
CZ82295A3 (en) * 1994-04-01 1995-12-13 Lilly Co Eli Derivative of 1h-indole-3-glyoxylamide and a pharmaceutical composition containing thereof

Also Published As

Publication number Publication date
AU757002B2 (en) 2003-01-30
BR9908479A (pt) 2000-12-05
ATE310513T1 (de) 2005-12-15
EP1058547A1 (en) 2000-12-13
TR200002543T2 (tr) 2000-11-21
WO1999044604A1 (en) 1999-09-10
WO1999044604A9 (en) 2000-01-20
DE69928500T2 (de) 2006-08-03
US6166062A (en) 2000-12-26
KR20010034552A (ko) 2001-04-25
CA2322796A1 (en) 1999-09-10
AU2799899A (en) 1999-09-20
HUP0102812A2 (hu) 2001-12-28
NO20004306D0 (no) 2000-08-29
PL342822A1 (en) 2001-07-02
NO20004306L (no) 2000-10-10
EA003864B1 (ru) 2003-10-30
ID27487A (id) 2001-04-12
JP2002505282A (ja) 2002-02-19
JP2011021042A (ja) 2011-02-03
EA200000897A1 (ru) 2001-02-26
DE69928500D1 (de) 2005-12-29
ES2253877T3 (es) 2006-06-01
TW570795B (en) 2004-01-11
NZ506578A (en) 2003-09-26
EP1058547B1 (en) 2005-11-23
CN1299277A (zh) 2001-06-13
JP2006096761A (ja) 2006-04-13
HUP0102812A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
IL138154A0 (en) Pharmaceutical compositions containing sodium [[3- (2-amino-1,2-dioxoethyl) -2-ethyl-1-) phenylmethyl) -1h-indol-4-yl]oxy] acetate
ES2208693T3 (es) Procedimiento mejorado para la estabilizacion de sustancias biologicas durante la deshidratacion y ulterior almacenamiento, y composiciones de dichas sustancias.
JP2019052167A (ja) 活性剤送達のための溶解性ゲル形成フィルム
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
ATE259656T1 (de) Immunoglobulin enthaltende zusammensetzung
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
EP0889733A4 (en) STABILIZED GROWTH HORMONE FORMULATION AND PROCESS FOR PREPARING THE SAME
AR025852A1 (es) Estabilizacion de acido ferulico en composiciones cosmeticas
JP2006182750A (ja) 凍結乾燥化粧品およびその製造方法
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
PL346764A1 (en) New oral formulation for 5-ht4
RU2005112202A (ru) Депо-препараты арилгетероциклических активных веществ в виде суспензии
RU2005101746A (ru) Жидкий препарат, содержащий олигопептиды и этерифицированный циклодекстрин
MY148518A (en) Crystalline parecoxib sodium
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
AU2804395A (en) Long-acting oxytetracycline composition
ATE268181T1 (de) Pharmazeutische zubereitungen enthaltend alginate
AU7532994A (en) Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt
HU184890B (en) Process for preparing an antimicrobial composition with increa sed staaility
IL153592A0 (en) A pharmaceutical composition containing ketoconazole
JPWO2003094889A1 (ja) 凍結乾燥物
ATE169630T1 (de) Zytostatisch wirksame anthracyclinderivate
ES2149736T1 (es) Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes.